source
- AstraZeneca puts $2 billion into Summit Therapeutics and partners to test ivonescimab with its oncology pipelineAstraZeneca announced a $2 billion equity investment in Summit Therapeutics, acquiring roughly 109,000 shares of convertible preferred stock. The deal will give AstraZeneca about a 12% stake in Sum…
- Beam Therapeutics sues YolTech and Serapha Bio over alleged theft of base editing trade secretsBeam Therapeutics has filed a lawsuit in U.S. District Court in Massachusetts accusing Chinese biotech YolTech Therapeutics and its U.S. partner Serapha Bio of using confidential information to dev…